Chronic Hbv Infection clinical trials

Explore recruiting chronic hbv infection clinical trials.

Recruiting chronic hbv infection studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Hbv Infection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects with Chronic HBV Infection

France, Spain, Poland, Romania

Therapeutic exploratory (Phase II) EU CTIS Study details

A first-time-in human (FTIH), Phase I/II, randomized, multi-centric, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GSK Biologicals’ HBV viral vector vaccines given in a prime-boost schedule with sequential or co-administration of adjuvanted proteins therapeutic vaccine (GSK3528869A) in chronic Hepatitis B patients (18-65 years old) well controlled under nucleo(s)tide analogue (NA) therapy.

Belgium, Germany, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1)

Spain, Romania, France, Hungary, Italy, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 2)

Romania, Germany, Poland, France, Hungary, Italy +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue (NA) treatment

Bulgaria, France, Italy, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

Chronic Hbv Infection trials by city

Chronic Hbv Infection in Toronto Chronic Hbv Infection in Vancouver Chronic Hbv Infection in Montreal Chronic Hbv Infection in Calgary Chronic Hbv Infection in Edmonton Chronic Hbv Infection in Ottawa Chronic Hbv Infection in Winnipeg Chronic Hbv Infection in Quebec City Chronic Hbv Infection in Hamilton Chronic Hbv Infection in Kitchener Chronic Hbv Infection in London Chronic Hbv Infection in Halifax Chronic Hbv Infection in New York Chronic Hbv Infection in Los Angeles Chronic Hbv Infection in Chicago Chronic Hbv Infection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease